Holen Sie sich die Stockscreener-App
88.74
0.45%
0.40
Handel nachbörslich:
88.90
0.16
+0.18%
Schlusskurs vom Vortag:
$88.34
Offen:
$88.87
24-Stunden-Volumen:
1.25M
Relative Volume:
2.98
Marktkapitalisierung:
$1.92B
Einnahmen:
$486.82M
Nettoeinkommen (Verlust:
$18.78M
KGV:
108.22
EPS:
0.82
Netto-Cashflow:
$100.45M
1W Leistung:
+28.44%
1M Leistung:
+36.61%
6M Leistung:
+49.92%
1J Leistung:
+50.53%
1-Tages-Spanne:
$87.87
$90.23
1-Wochen-Bereich:
$67.98
$90.23
52-Wochen-Spanne:
$52.50
$90.23
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
88.74 | 1.92B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals Inc. Surpasses Analyst Target Price of $83.12 - AInvest
ANI Pharmaceuticals Reports Record Growth in Q2 2025 - TipRanks
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2025 Earnings Call Transcript - Insider Monkey
What technical models suggest about ANI Pharmaceuticals Inc.’s comebackFree Trade Setups With AI Powered Filters - Newser
Truist Securities Adjusts ANI Pharmaceuticals Price Target to $77 From $65, Maintains Hold Rating - MarketScreener
Historical volatility pattern of ANI Pharmaceuticals Inc. visualizedSmart Entry Watchlist with Daily Analysis - Newser
Trend analysis for ANI Pharmaceuticals Inc. this weekFree Profit Target Stock Opportunity Monitor - Newser
How high can ANI Pharmaceuticals Inc. stock goFundamental + Technical Combined Watchlist - Newser
When is the best time to exit ANI Pharmaceuticals Inc.Real-Time Signal Tracking with Entry Level - Newser
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
ANI Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
ANI Pharmaceuticals Q2 2025 Earnings Call Highlights: Record Revenue, Raised Guidance, and Strong Growth - AInvest
Should I buy ANI Pharmaceuticals Inc. stock before earningsFree Swing Setup With Technical Confirmation - Newser
ANI Pharmaceuticals: A High-Growth Biopharma Play with Rare Disease and Generics Synergy - AInvest
Is ANI Pharmaceuticals Inc. stock poised for growthLow Risk Stock Selection Strategy Guide - Newser
Assessing ANI Pharmaceuticals' (ANIP) Growth Trajectory in Rare Diseases and Generics Amid Strategic and Financial Headwinds - AInvest
ANI Pharmaceuticals raises 2025 guidance to $843M revenue and $7.35 EPS as Cortrophin Gel accelerates - MSN
Advanced analytics toolkit walkthrough for ANI Pharmaceuticals Inc.Free Buy Signal Based on Chart Analysis - Newser
ANI Pharmaceuticals Receives Buy Rating and Optimistic Price Target - timothysykes.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Will ANI Pharmaceuticals Inc. rebound enough to break evenFree Short Term Buy List With Stop Protection - Newser
ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors - MSN
ANI Pharmaceuticals Inc. stock daily chart insightsFree Fundamental + Technical Hybrid Stock Tips - Newser
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 52-Week High Following Earnings Beat - Defense World
ANI Pharmaceuticals Inc (ANIP) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... By GuruFocus - Investing.com Canada
Published on: 2025-08-09 00:38:02 - Newser
ANI Pharmaceuticals' Q2 2025: Unpacking Contradictions in Cortrophin Growth and Market Dynamics - AInvest
ANI Pharmaceuticals stock price target raised to $93 from $84 at H.C. Wainwright - Investing.com Canada
ANI: Q2 Earnings Snapshot - Norwalk Hour
Quantitative breakdown of ANI Pharmaceuticals Inc. recent moveFree Low Risk Buy Zone Opportunity Watch - Newser
Ani Pharmaceuticals shares rise 18.40% intraday after beating Q2 revenue and EPS estimates, raising FY forecast. - AInvest
ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright - TipRanks
Why ANI Pharmaceuticals (ANIP) Stock Is Up Today - TradingView
ANI Pharmaceuticals Stock Surges After Buy Rating and Strong Price Target - StocksToTrade
ANI Pharmaceuticals Surges as Buy Rating Hits Market - timothysykes.com
ANI Pharmaceuticals Surges 19%: What's Fueling This Explosive Move? - AInvest
Earnings call transcript: ANI Pharmaceuticals Q2 2025 earnings beat forecasts - Investing.com
Transcript : ANI Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 08, 2025 - MarketScreener
ANI Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ani Pharmaceuticals stock hits 52-week high at 77.86 USD By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42 - TipRanks
Cg Oncology (CGON) Q2 Loss Widens 93% - The Motley Fool
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
ANI Pharmaceuticals Boosts FY25 Outlook; Stock Up 7%Update - Nasdaq
ANI Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2025 Guidance Raised - MarketScreener
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results - TradingView
ANI PHARMACEUTICALS INC SEC 10-Q Report - TradingView
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2: Strong Sales, Stock Soars - TradingView
ANI Pharmaceuticals beats Q2 revenue, EPS beats estimates and raises FY forecast - MarketScreener
(ANIP) ANI Pharmaceuticals Expects 2025 Revenue Range $818M$843M, vs. FactSet Est of $791.5M - MarketScreener
Record Q4 net revenues up 53.1% YoY to $211.4mln, raises FY23 guidance. - AInvest
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):